BMC Geriatrics (Mar 2024)

Sarcopenia in subjects with Alzheimer’s disease: prevalence and comparison of agreement between EGWSOP1, EGWSOP2, and FNIH criteria

  • Roberta Barone,
  • Giulia Bramato,
  • Valentina Gnoni,
  • Alessia Giugno,
  • Daniele Urso,
  • Chiara Zecca,
  • Salvatore Nigro,
  • Marco Filardi,
  • Giancarlo Logroscino

DOI
https://doi.org/10.1186/s12877-024-04890-w
Journal volume & issue
Vol. 24, no. 1
pp. 1 – 8

Abstract

Read online

Abstract Background Sarcopenia is an age-related clinical syndrome characterized by the progressive loss of muscle mass and muscle strength. It appears to be closely linked to dementia, particularly Alzheimer’s disease (AD); however, its prevalence among AD patients remains unclear. In this study, we assessed differences in sarcopenia prevalence between non-demented individuals and AD patients. Moreover, we assessed sex-specific differences in sarcopenia prevalence and explored the diagnostic value of the Muscle Quality Index (MQI) for diagnosing sarcopenia among AD patients. Method Cross-sectional study including 145 patients with probable AD and 51 older adults with normal cognition. Sarcopenia was diagnosed according to the criteria of the European Working Group on Sarcopenia in Older People (EWGSOP1 and EWGSOP2) and of the Foundation for the National Institutes of Health (FNIH). The MQI was computed as the ratio of handgrip strength to skeletal muscle mass. Results No significant difference in sarcopenia prevalence was observed between AD patients and controls. Prevalence ranged from 3.4 to 23.4% in AD patients and from 2 to 11.8% in controls, depending on diagnostic criteria. Prevalence was higher using EWGSOP1 and decreased using EWGSOP2 and FNIH. Prevalence was higher in males than in females with AD. The MQI was lower in AD patients than in controls (95%CI: − 0.23, − 0.05, p < 0.001), but displayed poor diagnostic accuracy in identifying sarcopenia cases. Conclusions AD patients and controls show comparable sarcopenia prevalence. Sarcopenia prevalence is higher in males than females among AD patients and higher when using EWGSOP1 compared to FNIH and EWGSOP2 criteria.

Keywords